Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx to Present at Barclays Global Healthcare Conference

GlobeNewswire March 9, 2020

Ultragenyx Announces Planned Transition of Chief Financial Officer

GlobeNewswire March 3, 2020

Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

GlobeNewswire February 27, 2020

Ultragenyx to Present at SVB Leerink Global Healthcare Conference

GlobeNewswire February 21, 2020

Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

GlobeNewswire February 13, 2020

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update

GlobeNewswire February 6, 2020

GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome

GlobeNewswire January 15, 2020

Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance

GlobeNewswire January 13, 2020

Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

GlobeNewswire January 13, 2020

Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire January 9, 2020

Ultragenyx to Present at 38?? Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2019

Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma

GlobeNewswire December 18, 2019

Ultragenyx to Present at Piper Jaffray 31st Annual Healthcare Conference

GlobeNewswire November 26, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 8, 2019

Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update

GlobeNewswire November 5, 2019

Ultragenyx to Host Conference Call for Third Quarter 2019 Financial Results and Corporate Update

GlobeNewswire October 30, 2019

Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire October 14, 2019

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

GlobeNewswire October 2, 2019

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)

GlobeNewswire September 30, 2019

Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)

GlobeNewswire September 10, 2019